Source · Select Committees · Science and Technology Committee (Commons)
Recommendation 25
25
Paragraph: 106
Require MHRA to clarify phage standards for clinical trials and GMP acquisition
Recommendation
We recommend that the MHRA sets out what standard of phages will be required for UK clinical trials and how GMP will be acquired by UK produced phages if they cannot be assessed by a clinical trial. This guidance should be published within six months of the publication of this report.
Paragraph Reference:
106
Government Response
A response document is linked to this report, dated 1 March 2024. Response attribution to this recommendation has not been verified. Read the response document ↗